DDrare: Database of Drug Development for Rare Diseases

Standard care (DrugBank: -)

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
81	先天性副腎皮質酵素欠損症	1
299	嚢胞性線維症	1

81. 先天性副腎皮質酵素欠損症　［臨床試験数：65，薬物数：77（DrugBank：20），標的遺伝子数：11，標的パスウェイ数：65］

Searched query = "Congenital adrenal hyperplasia", "Congenital adrenal enzyme deficiency", "Congenial adrenal cortex enzyme deficiency", "Congenital Lipoid Adrenal Hyperplasia", "3β-Hydroxysteroid Dehydrogenase Deficiency", "21-Hydroxylase deficiency", "11β-Hydroxylase deficiency", "17α-Hydroxylase deficiency", "P450 oxidoreductase deficiency", "Aldosterone synthase deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 65 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03532022 (ClinicalTrials.gov)	October 4, 2018	18/4/2018	Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy	An Open-label, Randomized, Titration-blinded, Phase III Study of Efficacy, Safety and Tolerability Of Chronocort® Compared With Standard Glucocorticoid REeplacement Therapy in the Treatment of Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia	Congenital Adrenal Hyperplasia	Drug: Chronocort®;Drug: Standard Care	Diurnal Limited	National Institutes of Health (NIH)	Suspended	16 Years	N/A	All	132	Phase 3	United States

299. 嚢胞性線維症　［臨床試験数：1,592，薬物数：1,539（DrugBank：255），標的遺伝子数：81，標的パスウェイ数：162］

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 1,592 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02894684 (ClinicalTrials.gov)	January 2017	1/9/2016	Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis	Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis. An Randomised, Crossover Pilot Study of AZLI Plus Intravenous Colistin® Versus Standard Dual Intravenous Therapy	Cystic Fibrosis;Infection;Pseudomonas	Drug: Aztreonam;Drug: Standard Care	Liverpool Heart and Chest Hospital NHS Foundation Trust	University of Liverpool	Completed	16 Years	65 Years	Male	16	Phase 4	United Kingdom